• Immunovant director Atul Pande exercised stock options for 1,500 shares at $8.43 on Aug. 28, 2026.
• He sold 1,500 shares at $43.27 the same day.
• Directly held shares ended at 116,731 following the transactions.
• Stock options beneficially owned fell to 65,181.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001764013-26-000103), on August 28, 2026, and is solely responsible for the information contained therein.